Optison (Perflutren)

Optison is an ultrasound contrast agent used in cardiac imaging pathways to improve image quality.

• Echocardiography (left ventricular opacification): Improves end‑diastolic and end‑systolic border detection.
• Myocardial perfusion imaging: Enhances detection of perfusion defects.
• Stress echocardiography: Provides clearer delineation of wall motion during pharmacologic stress.

• Perflutren forms a suspension of microbubbles that are intravenously administered. The microbubbles are highly reflective to ultrasound waves, producing strong acoustic signals that amplify backscatter from the blood pool. This enhances the contrast between cardiac chambers and surrounding tissues, allowing detailed assessment of ventricular function and myocardial perfusion during ultrasound examinations.

Optison may cause adverse reactions ranging from mild to severe.

Common Side Effects

• Flushing: Transient warmth and reddening of the skin.
• Headache: Mild to moderate headache occurring shortly after injection.
• Nausea: Temporary feeling of queasiness.
• Injection site discomfort: Minor pain or irritation at the IV site.
• Hypotension: Slight drop in blood pressure post‑administration.

Serious or Rare Side Effects

• Anaphylactoid reaction: Severe allergic‑type response requiring immediate medical attention.
• Acute respiratory distress: Sudden difficulty breathing.
• Cardiac arrhythmia: Irregular heart rhythm occurring during or after the procedure.
• Pulmonary hypertension exacerbation: Worsening of pre‑existing pulmonary pressure issues.
• Severe hypotension: Marked drop in blood pressure leading to syncope.

Before using Optison, clinicians should assess patient suitability and monitor for reactions.

• Contraindication: Known hypersensitivity to perflutren or any component of the formulation.
• Caution: Use with caution in patients with severe cardiopulmonary disease.
• Monitoring: Observe vital signs during and after administration.
• Pregnancy: Avoid use unless clearly indicated; safety not established.
• Breastfeeding: Discontinue if adverse effects observed in infant.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Optison has a limited interaction profile, but certain agents may influence its safety or efficacy.

Major Interactions (Avoid)

• Vasodilators: May potentiate hypotensive effects.

Moderate Interactions (Monitor Closely)

• Beta‑blockers: May mask signs of hypotension.
• Diuretics: May affect intravascular volume status.
• Sedatives: May enhance dizziness or fainting risk.
• ACE inhibitors: May contribute to blood pressure changes.
• Contrast agents (iodinated): Concurrent use may increase overall contrast load.